| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, Breast Imaging Division, Box 3808, Duke University
Medical Center, Durham, NC 27710.
2 Department of Medicine, Oncology Division, Box 3893, Duke University Medical
Center, Durham, NC 27710.
3 Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC
27710.
4 Department of Biostatistics and Bioinformatics, Box 3958, Duke University
Medical Center, Durham, NC 27710.
5 Department of Radiation Oncology, Radiation Physics Division, Box 3085, Duke
University Medical Center, Durham, NC 27710.
6 Department of Radiation Oncology, Box 3455, Duke University Medical Center,
Durham, NC 27710.
OBJECTIVE. This study was undertaken to evaluate the ability of MRI to accurately show residual primary breast malignancy in women treated with neoadjuvant chemotherapy.
MATERIALS AND METHODS. Twenty-one patients with locally advanced primary breast carcinoma underwent contrast-enhanced MRI before and after treatment with neoadjuvant anthracycline-based chemotherapy. For each patient, the maximum extent of the MRI abnormality was measured both before and after treatment. These measurements were subsequently compared with physical examination findings and histologic results to determine the ability of MRI to accurately reveal tumor extent after neoadjuvant chemotherapy.
RESULTS. MRI after chemotherapy showed a correlation coefficient of 0.75 with histology, which was better than physical examination (r = 0.61). MRI underestimated the extent of residual tumor in two patients by more than 1 cm (including one false-negative examination), was within 1 cm in 12 of 21 patients, and overestimated tumor extent by more than 1 cm in seven of 21 patients.
CONCLUSION. MRI can show residual malignancy after neoadjuvant chemotherapy better than physical examination, particularly in patients who have not had a complete clinical response to therapy.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Elsamaloty, M. S. Elzawawi, S. Mohammad, and N. Herial Increasing Accuracy of Detection of Breast Cancer with 3-T MRI Am. J. Roentgenol., April 1, 2009; 192(4): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Buchholz, C. D. Lehman, J. R. Harris, B. A. Pockaj, N. Khouri, N. F. Hylton, M. J. Miller, T. Whelan, L. J. Pierce, L. J. Esserman, et al. Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference J. Clin. Oncol., February 10, 2008; 26(5): 791 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Loibl, G. von Minckwitz, G. Raab, J.-U. Blohmer, S. D. Costa, B. Gerber, H. Eidtmann, S. Petrich, J. Hilfrich, C. Jackisch, et al. Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial Ann. Surg. Oncol., November 1, 2006; 13(11): 1434 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tozaki, T. Kobayashi, S. Uno, K. Aiba, H. Takeyama, H. Shioya, I. Tabei, Y. Toriumi, M. Suzuki, and K. Fukuda Breast-Conserving Surgery After Chemotherapy: Value of MDCT for Determining Tumor Distribution and Shrinkage Pattern Am. J. Roentgenol., February 1, 2006; 186(2): 431 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Shah, S. K. Shah, and K. V. Greatrex Current Role of Magnetic Resonance Imaging in Breast Imaging: A Primer for the Primary Care Physician J Am Board Fam Med, November 1, 2005; 18(6): 478 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Roubidoux, G. L. LeCarpentier, J. B. Fowlkes, B. Bartz, D. Pai, S. P. Gordon, A. F. Schott, T. D. Johnson, and P. L. Carson Sonographic Evaluation of Early-Stage Breast Cancers That Undergo Neoadjuvant Chemotherapy J. Ultrasound Med., July 1, 2005; 24(7): 885 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Partridge, J. E. Gibbs, Y. Lu, L. J. Esserman, D. Tripathy, D. S. Wolverton, H. S. Rugo, E. S. Hwang, C. A. Ewing, and N. M. Hylton MRI Measurements of Breast Tumor Volume Predict Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival Am. J. Roentgenol., June 1, 2005; 184(6): 1774 - 1781. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Koomen, E. D. Pisano, C. Kuzmiak, D. Pavic, and R. McLelland Future Directions in Breast Imaging J. Clin. Oncol., March 10, 2005; 23(8): 1674 - 1677. [Full Text] [PDF]
|
|
|
|
|
|
L. A. Newman and H. M. Kuerer Advances in Breast Conservation Therapy J. Clin. Oncol., March 10, 2005; 23(8): 1685 - 1697. [Full Text] [PDF]
|
|
|
|
 |
|
 N. E. Davidson and M. Morrow Sometimes a Great Notion--An Assessment of Neoadjuvant Systemic Therapy for Breast Cancer J Natl Cancer Inst, February 2, 2005; 97(3): 159 - 161. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
